FOSTER CITY (dpa-AFX) - Kite, a Gilead Sciences, Inc. Company (GILD),
announced Monday updated, four-year overall survival (OS) data from the pivotal
ZUMA-3 study evaluating the CAR T-cell therapy Tecartus (brexucabtagene
autoleucel) in adult patients with relapsed or refractory B-cell acute
lymphoblastic leukemia (R/R B-ALL).

The findings showed a median Overall Survival (OS) of 25.6 months and a
four-year OS rate of 40% in all treated patients with a safety profile
consistent with that observed in the three-year analysis.

ZUMA-3 is an ongoing international multicenter (US, Canada, Europe), single arm,
open label, registrational Phase 1/2 study of Tecartus in adult patients with
ALL whose disease is refractory to or has relapsed following standard systemic
therapy or hematopoietic stem cell transplantation.

The primary endpoint is the rate of overall complete remission or complete
remission with incomplete hematological recovery by central assessment.

The duration of remission and relapse-free survival, overall survival, minimal
residual disease (MRD) negativity rate, and alloSCT rate were assessed as
secondary endpoints.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX